Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients
Status:
Recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety for dose-dense epirubicin hydrochloride
with cyclophosphamide followed by nanoparticlealbumin-bound paclitaxel with PD-1 in
neoadjuvant therapy for patients with triple-negative breast cancer, and to explore the
predictive value of biological markers for the treatment.